Eye safety concerns may complicate the widespread adoption of GLP-1 receptor agonists as both diabetes treatments and weight-loss therapies. A case report documents an unexpected ocular side effect where dulaglutide, a weekly injectable diabetes medication, appeared to trigger abnormal lymphoid tissue proliferation in the choroid layer of the eye. The choroid, a vascular layer beneath the retina, developed hyperplastic lymphoid clusters that could potentially affect vision quality and retinal function. This represents the first documented association between this class of diabetes drugs and ocular lymphoid changes. The patient experienced visual disturbances that resolved after discontinuing the medication, suggesting a direct pharmaceutical cause rather than coincidental occurrence. GLP-1 receptor agonists like dulaglutide have gained significant attention beyond diabetes management due to their substantial weight-loss effects, leading to off-label prescribing and high patient demand. However, this ocular finding adds to growing awareness that these drugs may have systemic effects extending far beyond glucose regulation and appetite suppression. The choroidal involvement is particularly concerning because this tissue layer is critical for retinal nutrition and waste removal. While this appears to be an isolated case report rather than a pattern identified in large clinical trials, it highlights the importance of comprehensive safety monitoring as GLP-1 drugs become more widely prescribed. Eye examinations may warrant consideration for patients on long-term GLP-1 therapy, especially those reporting visual changes. This case represents early-stage safety data that could influence prescribing guidelines if additional cases emerge, though the overall risk-benefit profile of these medications remains favorable for most patients.